NeoGenomics stock
NEONASDAQNeoGenomics, Inc., HealthcareISIN US64049M2098
39Score 39 out of 100, Weak
Price and trend
71 / 100
Price history
+65% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 28% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 17% below its 52-week high. Largest decline in 20 years: 92% (February 2021 to July 2025).
Chart figures for advanced users
- SMA 50$17.58
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$12.97
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.19
- The lowest closing price of the last twelve months.
- Resistance$19.91
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- NeoGenomics, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $2.15B, is number 29 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $727.33M (up 10.1% year on year) and a loss of $108.03M.
- For fiscal 2026, analysts expect on average revenue of $808.2M (up 11.1%) and adjusted earnings per share of $0.20 (up 410%).
Show more
- MEQIRI Score 39 out of 100 (Weak): rank 552 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 10.4% a year since 2020, Medical (Diagnostics & Research) median 6.6%.
Weaknesses
- Loss-makingLoss of $32.3M over the last 12 months.Fundamentals 17
- Turned to a lossEarnings per share from $0.04 in 2020 to −$0.84.Growth 43
- Negative free cash flowFree cash flow −$28.58M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 39.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
OvervaluedNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 11.1% on the twelve months before. Revenue has grown strongly since 2006, at around 28% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 39%, operating −9%, net −15%. Last 12 months: net −4%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 16 Feb 2027in 95 days
- Last reported
- 28 Oct 2026EPS reported $0.07 (expected $0.06)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 8.7% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.20+8.9%
- Revenue
- $808.2M+0.4%
- Earnings per share
- $0.31−8.7%
- Revenue
- $888.03M+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.8%NeoGenomics raised its 2026 revenue guidance to $807 million to $809 million and its adjusted EBITDA guidance to approximately $60 million, both higher than previously guided.
“Given our strong third quarter, we are raising our full year '26 revenue guidance to a range of $807 million to $809 million, up from $802 million to $806 million discussed previously, and representing full year revenue growth of approximately 11% at the midpoint.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $440,224 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at NeoGenomics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 39
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- BillionToOneBLLN $5.29B64
- Sotera HealthSHC $4.65B54
- CareDxCDNA $4.19B59
- Vimian GroupVIMIAN.ST $2.23B58
- VeracyteVCYT $1.99B53
- PersonalisPSNL $1.72B41
- GeneDx HoldingsWGS $1.55B37
- OPKO HealthOPK $1.24B37
ETFs that hold NeoGenomics
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.20% | 0.40% | €813.42M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.12% | 0.30% | €2.31B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.08% | 0.30% | €185.82M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.08% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.08% | 0.30% | €4.28B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.05% | 0.10% | €395.74M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.05% | 0.43% | €2.5B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.03% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2020)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.